Skip to main content

Top header menu

  • Access to EMARKET SDIR
  • English
  • Italian
Home
EMARKET STORAGE - Teleborsa

Navigazione principale

  • Regulated Press releases
  • Regulated Documents
  • Support
  • Who we are
Menu

ALL Regulated Press Releases

Home Regulated Press releases
02/26/2024 - 17:50
PHARMANUTRA
PHN - Approval of the merger plan
01/11/2024 - 17:44
PHARMANUTRA
PR - PHN PRELIMINARY REVENUES 2023
01/11/2024 - 17:42
PHARMANUTRA
PHN - RICAVI PRELIMINARI 2023
01/08/2024 - 17:36
PHARMANUTRA
PHN: Perdita qualifica PMI - Loss of SME status
12/21/2023 - 15:24
PHARMANUTRA
PR Financial Calendar 2024
12/21/2023 - 15:21
PHARMANUTRA
CS Calendario Finanziario 2024
12/20/2023 - 11:08
PHARMANUTRA
Comunicazione di cessazione patto parasociale
11/10/2023 - 12:07
PHARMANUTRA
INTERIM MANAGMENT REPORT AS OF 30 SEPTEMBER 2023
11/10/2023 - 12:07
PHARMANUTRA
CS - DEPOSITO DEL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2023
11/08/2023 - 10:59
PHARMANUTRA
Allegato 3F - Ottobre 2023
11/06/2023 - 17:53
PHARMANUTRA
PHN - The BoD approved the Interim consolidated financial report as at 30 September 2023
11/06/2023 - 17:50
PHARMANUTRA
PHN - Il CdA approva il Resoconto Intermedio di Gestione al 30 settembre 2023
10/10/2023 - 18:19
PHARMANUTRA
PHN - Initiation of share buy-back program
10/10/2023 - 18:19
PHARMANUTRA
PHN - Avvio programma azioni proprie
10/03/2023 - 18:09
PHARMANUTRA
PR - FIRST SALES ON THE US MARKET
10/03/2023 - 18:02
PHARMANUTRA
CS - PRIME VENDITE SUL MERCATO AMERICANO
09/19/2023 - 10:15
PHARMANUTRA
Half-Year Financial Report as of 30 June 2023
09/19/2023 - 10:12
PHARMANUTRA
PHN-Pubblicazione della Relazione Finanziaria Semestrale al 30 giugno 2023
09/11/2023 - 17:53
PHARMANUTRA
FIRST HALF 2023 RESULTS
09/11/2023 - 17:49
PHARMANUTRA
RISULTATI PRIMO SEMESTRE 2023
08/30/2023 - 18:05
PHARMANUTRA
PR - Lipocet to be classified as a Novel Food also in UK
08/30/2023 - 17:58
PHARMANUTRA
CS - Lipocet autorizzata la classificazione come Novel Food nel Regno Unito
07/17/2023 - 18:13
PHARMANUTRA
PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT
07/17/2023 - 18:07
PHARMANUTRA
CS PHARMANUTRA - PHN - APPROVAZIONE BILANCIO DI SOSTENIBILITA' 2022

Pagination

  • First page « First
  • Previous page ‹ Precedente
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Current page 6
  • Page 7
  • Next page Seguente ›
  • Last page Last »

Footer menu

  • Disclaimer
  • Privacy
  • Cookies
  • Emergency assistance

Teleborsa - Logo

©Copyright 2022 Teleborsa S.r.l. No material on this site may be published, distributed, sold or reproduced in any form, whether printed or written, without the authorization of Teleborsa S.r.l.

  • Regulated Press releases
  • Regulated Documents
  • Support
  • Who we are